Bone destruction by receptor activator of nuclear factor κB ligand-expressing T cells in chronic gouty arthritis by Lee, Sung-Ji et al.
RESEARCH ARTICLE Open Access
Bone destruction by receptor activator of nuclear
factor B ligand-expressing T cells in chronic
gouty arthritis
Sung-Ji Lee
1†, Kwang-Il Nam
2†, Hye-Mi Jin
1, Young-Nan Cho
1, Song-Eun Lee
2, Tae-Jong Kim
1, Shin-Seok Lee
1,
Seung-Jung Kee
3, Keun-Bae Lee
4, Nacksung Kim
5* and Yong-Wook Park
1*
Abstract
Introduction: The purpose of this study was to analyze the cellular expressions of pro-resorptive cytokines in
gouty tophus tissues, to determine the capacity of monosodium urate monohydrate (MSU) crystals to induce these
cytokines, and to understand the mechanisms of bone destruction in chronic gout.
Methods: Fourteen fixed, paraffin-embedded, uninfected tophus samples were analyzed immunohistochemically.
Peripheral blood mononuclear cells (PBMCs) were cultured in vitro with MSU crystals, and gene expression was
assessed by reverse transcription-polymerase chain reaction. In vitro osteoclastogenesis was performed using
PBMCs and synovial fluid mononuclear cells (SFMCs).
Results: CD4+ T cells, CD8+ T cells, CD20+ B cells and mast cells infiltrated tophus tissues. Tartrate-resistant acid
phosphatase (TRAP)+ osteoclasts were present around tophi and in osteolytic lesions. Interleukin (IL)-1, IL-6 and
tumor necrosis factor (TNF)-alpha were produced from infiltrated mononuclear cells, whereas receptor activator of
nuclear factor B ligand (RANKL) was strongly expressed in T cells. However, osteoprotegerin (OPG) was not or was
weakly expressed in tophus tissues. MSU crystals induced the expressions of IL-1, IL-6, TNF-alpha and RANKL in
PBMCs, but inhibited OPG expression. In addition, the pro-resorptive cytokines were highly expressed in SFMCs of
gouty arthritis patients. Furthermore, in vitro osteoclastogenesis was enhanced in SFMC cultures, but inhibited in T
cell-depleted SFMC cultures.
Conclusions: Our study demonstrates that RANKL-expressing T cells and TRAP+ osteoclasts are present within gouty
tophus tissues, and that infiltrating cells express pro-resorptive cytokines. Furthermore, our data show that MSU crystals
have the potential to induce pro-resorptive cytokines, and T cells are involved in osteoclastogenesis in chronic gout.
Introduction
Gout is an inflammatory arthritis caused by the deposi-
tion of monosodium urate monohydrate (MSU) crystals
within joints during chronic hyperuricemia [1,2]. If left
untreated, acute attacks of gout can lead to chronic
gout, which is characterized by the presence of tophi,
synovitis, and bone erosion [3]. Eventually, chronic
tophaceous gout may lead to joint damage, deformity
and disability [4].
Gouty tophus appears to be composed of chronic granu-
lomatous lesions of mono- and multinucleated macro-
phages surrounding deposits of MSU crystals [5,6].
Macrophages are a major effector of inflammation, and are
continuously recruited into gouty tophi [7,8]. Recently, Dal-
beth et al. showed enhanced osteoclastogenesis in patients
with chronic tophaceous gout [9], and subsequently,
demonstrated that gouty tophi represent an organized
chronic inflammatory tissue response involving both innate
and adaptive immune cells to MSU crystals [10]. However,
the cellular mechanisms by which cytokines are involved in
* Correspondence: nacksung@jnu.ac.kr; parkyw@jnu.ac.kr
† Contributed equally
1Department of Rheumatology, Research Institute of Medical Sciences, Brain
Korea 21, Chonnam National University Medical School and Hospital, 42,
Jebong-ro, Dong-gu, Gwangju 501-757, South Korea
5National Research Laboratory for Regulation of Bone Metabolism and
Disease, Medical Research Center for Gene Regulation, Chonnam National
University Medical School, 42, Jebong-ro, Dong-gu, Gwangju 501-757, South
Korea
Full list of author information is available at the end of the article
Lee et al. Arthritis Research & Therapy 2011, 13:R164
http://arthritis-research.com/content/13/5/R164
© 2011 Lee et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.osteoclastogenesis in response to MSU crystals remain to
be clarified.
Osteoclasts are multinucleated cells, which are formed
by the fusion of mononuclear progenitors of the mono-
cyte/macrophage family [11,12], and are principally
responsible for bone resorption. Osteoclasts express tar-
trate-resistant acid phosphatase (TRAP), and their differ-
entiation and maturation are largely regulated by M-CSF
(macrophage colony-stimulating factor), RANKL (receptor
activator of nuclear factor B ligand, also known as OPGL
or TRANCE), and osteoprotegerin (OPG) [12,13]. Pre-
vious studies have demonstrated that RANKL serves as
both a chemotactic and survival factor for osteoclasts
[14,15], and its expression can be up-regulated by pro-
resorptive cytokines, such as interleukin (IL)-1, IL-6 and
tumor necrosis factor (TNF)-a [16-18].
In chronic inflammatory arthritis, such as rheumatoid
arthritis (RA) and psoriatic arthritis (PsA), osteoclasts have
been shown to play an important role in the pathogenesis
of bone erosion [19,20]. It was demonstrated in a recent
study that TRAP+ multinucleated cells (osteoclast-like
cells) were present within the corona zone of gouty tophus
[10]. Moreover, RANKL has been shown to mediate this
osteoclastogenesis in RA and PsA [21-23], and it has been
suggested that osteoclasts and the RANKL-RANK path-
way are important in mediating bone erosion formation in
gouty arthritis [24]. However, much less is known about
the cellular origin of RANKL-RANK and the histological
characteristic of TRAP+ multinucleated cells in gouty
tophus. Furthermore, the role of RANKL-expressing cells
during osteoclastogenesis in gouty arthritis remains to be
clarified.
MSU crystals provide a proinflammatory stimulus that
can initiate, amplify, and sustain an intense inflammatory
response, because this stimulus induces the synthesis and
release of humoral and cellular inflammatory mediators
[25]. Furthermore, these crystals can interact with mast
cells, endothelial cells, neutrophils, macrophages or syno-
vial fibroblasts by phagocytosis or direct interaction with
cell surface receptor, thus triggering a typical inflammatory
response through the release of proinflammatory cytokines,
such as IL-1b, IL-6, IL-8 and TNF-a [25-27]. These find-
ings suggest that MSU crystals might trigger the inflamma-
tory response observed in gouty arthritis. The aim of the
present study was to analyze the cellular expressions of
pro-resorptive cytokines in gouty tophus tissues, to deter-
mine the capacity of MSU crystals to induce these cyto-
kines, and finally to understand the cellular mechanisms of
bone destruction in chronic gouty arthritis.
Materials and methods
Sample collections
Fourteen gouty tophus tissues were obtained from eight
patients with chronic gout who underwent surgery for
the removal of tophi. The clinical features of the
patients and tophi are summarized in Table 1. Six
paired samples of peripheral blood and synovial fluid
were obtained from gouty arthritis patients with knee
effusion. The presence of MSU crystals in tophus and
synovial fluid samples was confirmed by polarizing light
Table 1 Patient and tophus characteristics at the time of surgery
a
Patient characteristics (n =8 )
No. (%) male 7 (88)
Age, median (range) years 46 (31 to 67)
Duration of gout, median (range) years 12 (4 to 30)
No. (%) prescribed allopurinol 6 (75)
No. (%) prescribed colchicine 7 (87.5)
No. (%) prescribed nonsteroidal anti-inflammatory drugs 2 (25)
Serum urate, median (range) mg/dl 6.6 (5 to 9.8)
CRP, median (range) mg/dl 0.84 (0.2 to 4.3)
Tophus characteristics (n = 14)
Duration of tophus, median (range) years 5 (1.5 to 7)
Location of tophus
First MTP joint, No. (%) 7 (50)
Ankle joint, No. (%) 4 (29)
Elbow joint, No. (%) 2 (14)
Hand PIP joint, No. (%) 1 (7)
Indication for surgery
Mechanical problem, No. (%) 10 (71)
Pain control, No. (%) 4 (28)
Sepsis control (infected/ulcerated tophi), No. (%) 0 (0)
CRP, C-reactive protein; MTP, metatarsophalangeal; No., number; PIP, proximal interphalangeal.
aData are presented as medians and ranges or percentages.
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Review Board of Chonnam National University Hospital,
and written informed consent was obtained from all
participants.
Immunohistochemistry
Gouty tophus tissue samples were fixed in neutral buf-
fered formalin and embedded in paraffin. Bone samples
were demineralized at room temperature in 10% formic
acid for one week and then embedded in paraffin. Con-
secutive 6-μm sections were immunohistochemically
stained using LSAB2 System-HRP kit (DakoCytomation,
Carpentaria, CA, USA). Briefly, sections were deparaffi-
nized, hydrated and placed in a peroxidase block solu-
tion for 10 minutes. After washing with phosphate
buffered saline (PBS), sections were incubated with pri-
mary antibodies or isotype controls for 2 hours, treated
with biotinylated link solution for 20 minutes, incubated
in streptavidin-HRP solution for 20 minutes, treated
with diaminobenzidine (DAB) chromogen solution for
10 minutes, and counterstained with hematoxylin. Sec-
tions were then mounted using Vectorshield mountant
(Vector Laboratories, Burlingame, CA, USA) and ana-
lyzed by light microscopy (Olympus, Tokyo, Japan).
The following anti-human primary antibodies and
dilutions were used: rabbit anti-CD3 polyclonal antibody
(pAb) at a dilution of 1:100 (DakoCytomation, Produk-
tionsvej, Denmark), mouse anti-CD4 monoclonal anti-
body (mAb) at 1:100 (clone IF6; Novocastra, Newcastle-
upon-Tyne, UK), mouse anti-CD8 mAb at 1:100 (clone
144B; DakoCytomation), mouse anti-CD20 mAb at
1:400 (clone L26; DakoCytomation), mouse anti-CD68
mAb at 1:200 (clone Kp-1; Cell Marque, Rocklin, CA,
USA), mouse anti-c-kit mAb at 1:100 (clone 104D2;
DakoCytomation), mouse anti-IL-1b mAb at 1:500
(clone 8516; R&D Systems, Minneapolis, MN, USA),
mouse anti-IL-6 mAb at 1:500 (clone 1936; R&D Sys-
tems), mouse anti-TNF-a mAb at 1:100 (clone 28401;
R&D Systems), mouse anti-RANKL mAb at 1:100 (clone
70525, R&D Systems), mouse anti-RANK mAb at 1:400
(clone 80707; R&D Systems), and goat anti-OPG pAb at
1:20 (R&D Systems).
For TRAP staining, deparaffinized sections were
hydrated, incubated in TRAP staining solution (Sigma,
Poole, UK) overnight at 37°C, counterstained with
hematoxylin, and then mounted using GVA mount
(Zymed, San Francisco, CA, USA).
Immunofluorescence and confocal microscopic
examination
Deparaffinized sections were hydrated and then incu-
bated with mouse anti-human RANKL mAb at 1:300
(R&D Systems) for 30 minutes at room temperature.
After washing three times with PBS, sections were
treated with Cy3-AffiniPure Fab fragment donkey anti-
mouse IgG (Jackson Immunoresearch, West Grove, PA,
USA), incubated with rabbit anti-human CD3 pAb at
1:100 (Dako) overnight at 4°C, washed with PBS, and
treated with fluorescein isothiocyanate (FITC)-Affini-
Pure Fab fragment donkey anti-rabbit IgG (Jackson
Immunoresearch). Sections were mounted using Vector-
shield mountant (Vector) and analyzed by LSM 510
confocal laser microscopy (Zeiss, Jena, Germany).
Electron microscopic examination of osteoclasts
Multinucleated giant cells were processed for morpholo-
gic evaluation by transmission electron microscopy as
previously described [28]. Briefly, tissue samples were
fixed in Karnovsky’s fixative (2% paraformaldehyde plus
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer
(pH 7.4) for two hours at 4°C. After rinsing three times
for 20 minutes in the same buffer, samples were post-
fixed in 1% osmium tetroxide (in 0.1 M sodium cacody-
late buffer), dehydrated in a graded ethyl alcohol series,
and embedded in Epon (EMbed 812; Electron Micro-
scopy Sciences, Hatfield, PA, USA). The samples were
then sectioned at 70 nm using a Leica EM UC6 ultrami-
crotome (Leica, Wetzlar, Germany), stained with lead
citrate and alcoholic uranyl acetate, and examined under
a JEM 1200EX-II transmission electron microscope
(JEOL, Tokyo, Japan).
MSU crystal synthesis
MSU crystals were prepared by recrystallization from
uric acid as previously described [29]. Briefly, 0.4 gm of
uric acid was dissolved in 80 ml of boiling distilled
water containing 2.45 ml of 1N NaOH. After adjusting
the pH of the solution to 7.2 with HCl, the solution was
g r a d u a l l yc o o l e db ys t i r r i n ga tr o o mt e m p e r a t u r ea n d
stored overnight at 4°C. The crystals that formed were
sterilized by heating at 180°C for two hours and sus-
pended in PBS at a concentration of 1 mg/ml. The crys-
tals obtained by this method were of comparable size (5
to 25 μm long) and needle-shaped, negatively birefrin-
gent crystals observed by compensated polarized light
microscopy. Endotoxin levels in MSU crystal prepara-
tions, as assessed by Limulus amoebocyte cell lysate
assay (Lonza, Walkersville, MD, USA), were less than
0.01 endotoxin IU/ml.
Isolation of peripheral blood mononuclear cells (PBMCs),
synovial fluid mononuclear cells (SFMCs), monocytes and
T cells
Peripheral venous blood and synovial fluid samples were
collected in heparin containing tubes. PBMCs and
SFMCs were isolated by density-gradient centrifugation
using Ficoll-Paque Plus solution (Amersham Bioscience,
Uppsala, Sweden). Monocytes and T cells were isolated
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ads or Pan T Cell Isolation Kit II (Miltenyi Biotec,
Bergisch Gladbach, Germany), respectively, and T cell
depletion from SFMCs was performed using Pan T cell
isolation Kit II (Miltenyi Biotec), according to manufac-
turers’ instructions.
Co-culture of PBMCs, monocytes and T cells with MSU
crystals
Freshly isolated PBMCs, monocytes or T cells were sus-
pended in a complete medium, which consisted of RPMI
1640, 2 mM L-glutamine, 100 units/ml of penicillin, and
100 μg/ml of streptomycin, supplemented with 10% fetal
bovine serum (FBS; Gibco BRL, Grand Island, NY, USA),
and then seeded in triplicate in six-well plates at 3 × 10
6
cells/well. After different concentrations of MSU crystals
(0, 50, 100, and 250 μg/ml) were added directly to the cul-
ture plates, cells were cultured in completed media for the
indicated times (4 hours for IL-1a, IL-1b, IL-6, and TNF-
a, and 72 hours for RANKL and OPG) with at 37°C in a
5% CO2 humidified incubator. Cells were then harvested
for RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR) analysis.
Suspended cells were seeded in triplicate in six-well
plates at 3 × 10
6 cells/well, and then cultured in complete
media for the indicated times (4 hours for IL-1a,I L - 1 b,
IL-6, and TNF-a, and 72 hours for RANKL and OPG)
with different concentrations of MSU crystals (0, 50, 100,
and 250 μg/ml) at 37°C in a 5% CO2 humidified incubator.
Cells were then harvested for RNA extraction and reverse
transcription-polymerase chain reaction (RT-PCR)
analysis.
In vitro differentiation of PBMCs, SFMCs and T cell-
depleted SFMCs into osteoclasts
PBMCs, SFMCs and T cell-depleted SFMCs were differ-
entiated to osteoclasts as described previously [9,22,30].
Briefly, freshly isolated PBMCs, SFMCs and T cell
depleted SFMCs from patients with gouty arthritis were
seeded in a 96-well plate at 3 × 10
5 cells/well, and then
cultured for 10 days in a-minimum essential medium
(a-MEM; HyClone Laboratories, Logan, UT, USA) sup-
plemented with 10% FBS in the presence of a mixture
of M-CSF (30 ng/ml; PeproTech, London, UK) and dif-
ferent concentrations (0, 10, and 100 ng/ml) of RANKL
(PeproTech). The culture medium was replaced every
three days. The cells were fixed and stained for TRAP
(Sigma, St. Louis, MO, USA). TRAP+ cells with three or
more nuclei were defined as osteoclasts, and the number
of osteoclasts was counted in triplicate.
RT-PCR and real-time PCR
RT-PCR and real-time PCR were performed as previously
described [31,32]. Briefly, total RNA was extracted from
cultured cells using TRIzol (Invitrogen, Carlsbad, CA,
USA). First-strand cDNA was transcribed from 1 μgo f
RNA using Superscript RT (Invitrogen), according to the
manufacturer’s instructions. To determine the expression
levels of specific genes and of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) (used as an internal con-
trol), PCRs were performed using QuantiTect SYBR
Green PCR kits (Qiagen, Valencia, CA, USA) in triplicate
in a Rotor-Gene 3000 (Corbett Research, Mortlake,
NSW, Australia), using the following conditions; 15 min-
utes at 95°C, followed by 40 amplification cycles of 95°C
for 30 seconds, 58°C for 30 seconds, and 72°C for 30 sec-
onds. All quantitations were normalized versus endogen-
ous GAPDH. The relative quantitation value of each
target gene as compared with the calibrator for that tar-
get was calculated using 2
-(Ct-Cc) (Ct and Cc are the mean
threshold cycle differences after normalizing to GAPDH).
Relative expression levels are presented using semilog
plots. PCR products were subjected to electrophoresis
and visualized by ethidium bromide staining. The
sequences of the primers used were as follows: for
GAPDH, 5’-CCATGGGGAAGGTGAAGGTCGGAG-3’
(sense) and 5’-TCAGCAGAGGGGGCAGAGATGATG-
3’ (antisense); for IL-1a,5 ’-CCAAGATGAAGACCAAC-
CAGTGC-3’ (sense) and 5’-TAGTGCCGTGAGTTTCC-
CAGAAG-3’ (antisense); for IL-1 b,5 ’-TGGCTTATT
ACAGTGGCAATGAGG-3’ (sense) and 5’-GTAGTGG
TGGTCGGAGATTCGTAG-3’ (antisense); for IL-6, 5’-
TGGTGTTGCCTGCTGCCTTC-3’ (sense) and 5’-CCA
GTGCCTCTTTGCTGCTTTC-3’ (antisense); for TNF-a,
5’-GGCTCCAGGCGGTGCTTG-3’ (sense) and 5’-GGG
CTACAGGCTTGTCACTCG-3’ (antisense); for RANKL,
5’-GCAGAGAAAGCGATGGTGGATG-3’ (sense) and
5’-GGGATGTCGGTGGCATTAATAGTG-3’ (anti-
sense); and for OPG, 5’-ATGCAACACACGACAAC
ATA-3’ (sense)and 5’-GTTGCCGTTTTATCCTCTCT-3’
(antisense).
Statistical analysis
Data are shown as median (range) or mean (standard
error of measurement, SEM). Wilcoxon signed rank test
was used for the comparison of changes in osteoclasto-
genesis of SFMCs after T cell depletion. P-values less
than 0.05 were considered statistically significant. All
statistical analyses were performed using SPSS version
17.0 software (SPSS, Chicago, IL, USA).
Results
Infiltration of chronic inflammatory cells into gouty
tophus tissues
Tophus samples were processed for hematoxylin-eosin
(H&E) and immunohistochemical staining (Figure 1).
Tophus lesions were observed within or around bone tis-
sues. Osteolytic lesions were observed in close proximity
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cleated or multinucleated giant cells. Many inflammatory
cells were found to have infiltrated stroma in tophi (Fig-
ure 1A), and immunohistochemistry showed that these
infiltrated cells stained positively for CD3, CD4, CD8,
CD20, or c-kit (a marker of mast cells). Furthermore,
CD68 was strongly expressed in tophus-lining multinu-
cleated giant cells and in some infiltrating cells
(Figure 1B).
CD68+ and TRAP+ multinucleated cells in gouty tophus
tissues
To identify osteoclasts in tophi, TRAP staining was per-
formed on serial tissue sections. In contrast to CD68,
which was found to be expressed by immunohistochem-
istry in tophus-lining cells and some stromal tissue-infil-
trating cells, TRAP was strongly expressed in
multinucleated giant cells, which were located around
tophi and in osteolytic lesions, but was not expressed in
stromal tissue-infiltrating cells (Figure 2A, B). Next, we
examined the ultrastructure of CD68+ and TRAP+ mul-
tinucleated giant cells around tophi by electron micro-
scopy. These cells had variable numbers of nuclei (up to
20 nuclei), several Golgi complexes, rough endoplasmic
reticulum, and numerous vesicles, which are characteris-
tics of osteoclasts. However, no ruffled border or clear
zone, characteristic of mature osteoclasts, was observed
(Figure 2C, D). Collectively, these observations suggest
that TRAP+ multinucleated osteoclast-like cells domi-
nate in gouty tophi.
Expression of pro-resorptive cytokines, RANKL and RANK
in gouty tophus tissues
To examine the expressions of pro-resorptive cytokines
in tophi, we performed immunohistochemistry using
anti-IL-1b, anti-IL-6, anti-TNF-a, and anti-RANKL anti-
bodies. These cytokines were found to be expressed in
both peritophi and stromal infiltrates (Figure 3A). Next,
RANK and OPG staining was performed to identify the
RANKL-OPG-RANK axis within the tophus. RANK was
strongly expressed in multinucleated giant cells, which
were located around tophi and in osteolytic lesions. In
contrast to TRAP, RANK was also expressed in some
stromal tissue-infiltrating cells. However, OPG was spar-
sely expressed in some mononuclear cells (Figure 3B).
It has been reported that activated T cells strongly
express RANKL in inflammatory regions [33,34]. There-
fore, to investigate whether RANKL is expressed in T
cells in tophi, tissue sections were stained by double-
immunofluorescent labeling and examined by confocal
microscopy. We found that RANKL-expressing cells
were positive for CD3, which suggested that CD3+ T
cells are cellular origin of RANKL (Figure 3C).
Induction of pro-resorptive cytokines by MSU crystals
Given our observation that pro-resorptive cytokines are
expressed in gouty tophi, we investigated the ability of
MSU to induce the cytokines involved in osteoclasto-
genesis (Figure 4). Freshly isolated PBMCs from healthy
donor subjects were stimulated with MSU crystals for
the indicated times, and the mRNA levels of several
Figure 1 Infiltration of chronic inflammatory cells in gouty tophus tissues. (a) Tophus tissue sections from patients with chronic gouty
arthritis were processed for hematoxylin-eosin (HE) staining. * indicates monosodium urate monohydrate (MSU) crystals, and ** represents
osteolytic lesions. (b) Serial sections were processed for immunohistochemical staining using anti-CD3, anti-CD4, anti-CD8, anti-CD20, anti-CD68,
and anti-c-kit antibodies (brown). Scale bar in a = 500 μm; scale bars in b = 50 μm.
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MSU crystals were found to strongly induce IL-1a,I L -
1b,I L - 6a n dT N F - a after four hours and their expres-
sions gradually decreased. In contrast, RANKL was
induced by MSU at 24 hours and then gradually
increased up to 72 hours. However, OPG was expressed
at baseline and down-regulated by MSU crystals (Figure
4A). Next, we cultured PBMCs for the indicated times
with increasing concentrations of MSU crystals, and
examined the mRNA expressions of IL-1a,I L - 1 b,I L - 6 ,
TNF-a, RANKL and OPG. MSU crystals were found to
induce these cytokines dose-dependently with the excep-
tion of OPG (Figure 4B). Collectively, our data suggest
that MSU crystals can induce pro-resorptive cytokines
and inhibit OPG expression.
To identify the cellular source of the pro-resorptive
cytokines induced by MSU, monocytes and T cells iso-
lated from healthy control subjects by magnetic-acti-
vated cell sorting were stimulated with MSU crystals for
the indicated times. The mRNA levels of the pro-resorp-
tive cytokines were then determined by RT-PCR. It was
found that IL-1a,I L - 1 b and TNF-a were primarily pro-
duced by monocytes, but that IL-6 was produced by
monocytes and T cells, and RANKL was produced by T
cells alone (Figure 4C, D).
Expression of pro-resorptive cytokines in the synovial
fluid of patients with gouty arthritis
To examine the expressions of IL-1a,I L - 1 b, IL-6, TNF-
a, RANKL and OPG in patients with gouty arthritis, six
Figure 2 Localization of CD68+ and tartrate-resistant acid phosphatase (TRAP)+ cells in gouty tophus tissues. (a) Tophus tissue sections
from patients with chronic gouty arthritis were processed for immunohistochemical staining using anti-CD68 antibody (brown). (b) Serial
sections were stained for TRAP (red). (c, d) Electron microscopic findings of CD68+ cells. Scale bars in left panels of a and b = 500 μm; scale
bars in right panels of a and b = 50 μm; scale bars in c and d = 5 μm.
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arthritis were processed for immunohistochemical staining using anti-interleukin (IL)-1b, anti-IL-6, anti-tumor necrosis factor (TNF)-a, anti-receptor
activator of nuclear factor B (RANK), anti-osteoprotegerin (OPG), and anti-receptor activator of nuclear factor B ligand (RANKL) antibodies
(brown). T, gouty tophus. (c) Immunofluorescent stains for CD3 (green) and RANKL (red) in tophaceous gout tissues. Scale bars in a, b, and c =
50 μm.
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were obtained from gouty arthritis patients with knee
effusion, and mRNA levels were determined by RT-PCR
and real-time PCR. MSU crystals were detected in syno-
vial fluid samples by compensated polarized light micro-
scopy (data not shown). As was expected, all five pro-
resorptive cytokines, such as IL-1a,I L - 1 b,I L - 6 ,T N F - a
and RANKL, with the exception of OPG, were found to
be strongly expressed in SFMCs, but to be only weakly
or not expressed in PBMCs (Figure 5A, B).
T cell-mediated osteoclastogenesis of SFMCs from
patients with gouty arthritis
To examine whether increased pro-resorptive cytokines in
the synovial fluid of patients with gouty arthritis have influ-
ence on osteoclast formation, osteoclasts were generated
from PBMCs and SFMCs in vitro as described in Patients
and Methods. Following culture with M-CSF only, no dif-
ferences were found between the numbers of TRAP+ mul-
tinucleated cells generated from PBMCs and SFMCs.
However, SFMCs were found to have the preferential
Figure 4 Expression of pro-resorptive cytokines by monosodium urate monohydrate (MSU) crystals. (a) Freshly isolated peripheral blood
mononuclear cells (PBMCs) from healthy control subjects were cultured for the indicated times (hours) in the presence of MSU crystals (100 μg/
ml). (b) PBMCs from same donors were cultured for the indicated times (that is, 4 hours for cytokines and 72 hours for receptor activator of
nuclear factor B ligand RANKL) at various MSU crystal concentration (μg/ml). (c, d) Monocytes and T cells were isolated from PBMCs by
magnetic-activated cell sorting. Freshly isolated monocytes and T cells from healthy control subjects were cultured for the indicated times
(hours) in the presence of MSU crystals (100 μg/ml). Total RNA was collected at each time point and at the different MSU crystal concentrations.
Reverse transcription-polymerase chain reaction (RT-PCR) was performed to determine the expressions of interleukin (IL)-1a, IL-b, IL-6, tumor
necrosis factor (TNF)-a, osteoprotegerin (OPG), and RANKL. Results are representative of three independent experiments.
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samples of peripheral blood and synovial fluid were obtained from gouty arthritis patients with knee effusion. (a, b) Expression of mRNA for
interleukin (IL)-1a, IL-b, IL-6, tumor necrosis factor (TNF)-a, receptor activator of nuclear factor B ligand (RANKL) and osteoprotegerin (OPG) in
peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs). Reverse transcription-polymerase chain reaction (RT-
PCR) (a) and real-time PCR (b) were performed to determine the mRNA expression of each gene. (c, d) T cell involvement in osteoclastogenesis
of SFMCs from patients with gouty arthritis. PBMCs, SFMCs, and T cell-depleted SFMCs (3 × 10
5 cells/well) were cultured for 10 days in the
presence of macrophage colony-stimulating factor (M-CSF; 30 ng/ml) at the different RANKL concentrations and then were stained for tartrate-
resistant acid phosphatase (TRAP). TRAP-positive multinucleated cells (MNCs) were counted in triplicate. Results are representative of six
independent experiments (a and upper panels in c and d). Data in b and lower panel in c are means ± SEMs. Scale bars in c and d = 50 μm.
*=P < 0.05, by Wilcoxon signed rank test.
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RANKL as compared with PBMCs (Figure 5C).
Next, to investigate the role of synovial fluid T cells in
osteoclastogenesis, we established T cell-depleted SFMC
cultures from six patients with gouty arthritis. TRAP+
multinucleated cells (mean ± SEM cell number 210 ± 36
cells/well) were efficiently generated from SFMCs of gouty
arthritis patients in the presence of 30 ng/ml of M-CSF
and 10 ng/ml of RANKL. In contrast, the formation of
TRAP+ multinucleated cells in T cell-depleted SFMC cul-
tures was significantly reduced (mean ± SEM cell number
78 ± 16 cells/well) (P = 0.028) (Figure 5D). These findings
suggest that synovial fluid T cells are involved in osteoclas-
togenesis of SFMCs from patients with gouty arthritis.
Discussion
The present study showed that various chronic inflamma-
tory cells infiltrated gouty tophi and that cytokines, which
induce bone resorption, were produced by these cells. In
addition, RANKL-expressing T cells and TRAP+ multinu-
cleated osteoclasts (both key players in osteoclastogenesis)
were observed in tophi samples. These findings suggest
that gouty tophi promote bone resorption in chronic gout.
Furthermore, our in vitro experiments showed that MSU
crystals induced IL-1, IL-6, TNF-a and RANKL, and all
were found to be highly expressed in the SFMCs of
patients with gouty arthritis. In addition, in vitro osteoclas-
togenesis was found to be T cell-dependent. Thus, our
study demonstrates that chronic inflammatory responses
to MSU crystals contribute to tophus formation and bone
destruction in chronic gout.
Gouty tophus has a complex, organized microstructure.
Acini of macrophages were found to have formed around
MSU crystals, and surrounding interstitial tissues were dif-
fusely infiltrated by chronic inflammatory cells, including
T cells, B cells, and mast cells. This microstructure of
tophus has also been reported previously [5,7,10]. Interest-
ingly, we found a predominance of CD8+ T cells over
CD4+ T cells in tophi as opposed to the slight augmenta-
tion of CD4+ T cells over CD8+ T cells reported in rheu-
matoid synovium [35,36]. Furthermore, the arrangements
of infiltrating cells in tophi were found to resemble a sub-
type of rheumatoid synovitis (diffuse synovitis) [37,38].
In the present study, CD68+RANK+TRAP+ osteoclasts
were observed in osteolytic lesions and, interestingly, we
also observed CD68+RANK+TRAP+ multinucleated cells
adjacent to MSU crystals. Electron microscopic observa-
tions revealed that these cells had the cytological features
of osteoclasts, that is, one or more perinuclear Golgi appa-
ratus, vesicular or tubular membrane-bounded granules,
rough endoplasmic reticulum, and many nuclei, but they
did not have the ruffled border or sealing zone. The defect
of sealing zone in these osteoclast-like cells might be due
to the absence of signal molecules provided by bone
matrix. It has been previously suggested that preosteo-
clasts may differentiate into osteoclasts by direct contact
with bone surface exposed by osteoblast detachment [39].
Thus, our data indicate that TRAP+ osteoclast-like cells
around tophi have the potential to become authentic
mature osteoclasts and contribute to bony erosion in
chronic gout.
Our interesting and novel observation concerned the
presence of RANKL-expressing T cells in gouty tophus tis-
sues. RANKL and OPG are key regulators of osteoclasto-
genesis [12], and it has been previously reported that
RANKL-expressing T cells are involved in osteoclastic
bone resorption in RA patients and in animal models of
inflammatory arthritis [33,34]. In the present study, we
demonstrated that RANKL was expressed in the tissue-
infiltrated T cells. In contrast, OPG was found to be not
or to be weakly expressed in the tophus tissues. In addi-
tion, proinflammatory cytokines (IL-1, IL-6, and TNF-a)
were found to be expressed in infiltrating mononuclear
cells. These cytokines are also known to participate in
bone resorption, and to potently induce and accelerate
RANKL signaling [40]. Accordingly, the expression of
RANKL and proinflammatory cytokines in the tophus tis-
sues strongly supports the histological evidence of osteo-
clastogenesis in chronic gout.
Our in vitro experiments demonstrate that MSU crystals
induce the proinflammatory cytokines, IL-1, IL-6 and
TNF-a, which are also expressed in tophus tissues. These
cytokines were strongly induced after four hours in mono-
cytes, indicating that MSU crystals induce innate immune
responses, which is consistent with previous findings
[41-43]. In addition, these cytokines are also present in the
joint fluids of patients with gouty arthritis. SFMCs, which
are under the milieu of various proinflammatory cytokines,
showed more enhanced osteoclastogenesis than PBMCs,
which findings are in agreement with data from Dalbeth et
al. [9]. The finding that MSU crystals can induce RANKL
expression in peripheral blood T cells is also interesting.
In contrast to the early induction of proinflammatory
cytokines (that is, IL-1, IL-6 and TNF-a), RANKL expres-
sion peaked after stimulation with MSU crystals for 72
hours, and RANKL was predominantly expressed by
T cells, not monocytes. These findings are relevant to
those of a recent study, which showed that uric acid can
directly promote T cell activation in an antigen-indepen-
dent manner [44]. To investigate the biological relevance
of T cells in osteoclastogenesis of gouty arthritis, we evalu-
ated osteoclastogenesis in T cell-depleted SFMC cultures.
As shown in Figure 5C, osteoclasts were not efficiently dif-
ferentiated from SFMCs in culture with M-CSF only, sug-
gesting that endogenous RANKL in SFMCs is not enough
to generate osteoclasts. Thus, 10 ng/ml of soluble RANKL
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with SFMCs cultures, osteoclastogenesis in T cell-depleted
SFMC cultures was reduced by approximately 60%, not
fully because of soluble RANKL (Figure 5D). These find-
ings suggest that T cells, at least, in part play a role in
osteoclast formation. Furthermore, it has been previously
reported that activated T cells are involved in osteoclasto-
genesis through RANKL [33], and RANKL was found to
be strongly expressed in SFMCs (Figure 5A, B). Thus,
endogenous RANKL in synovial fluid T cells could contri-
bute to osteoclastogenesis. Our results are consistent with
literature data demonstrating that T cells are involved in
the osteoclastogenesis of chronic inflammatory arthritis
[30,34]. Taken together, our data suggest that the induc-
tion of pro-resorptive cytokines and formation of RANKL-
expressing T cells by MSU crystals contribute to osteoclas-
togenesis in chronic gouty arthritis.
Our histological data show that adaptive immunity is
related to the development of gouty tophi. In particular,
T cells and B cells were found to have diffusely infiltrated
around the tophi. Cells of the monocyte and macrophage
lineages have previously been implicated in the develop-
ment of bone erosion in gout [8,45]. In addition, chronic
inflammatory conditions, such as RA and chronic
tophaceous gout, can lead to the activation of circulating
monocytes and promote their differentiation toward the
osteoclast lineage [9,46]. Furthermore, recently, Li et al.
demonstrated that osteoclasts function as antigen pre-
senting cells and that they stimulate both CD4+ and CD8
+ T cells [47]. Thus, based on our results and those of
others [9,10,24,48], we propose a possible model of bone
destruction in chronic gouty arthritis. MSU crystals
induce the productions of proinflammatory cytokines,
such as IL-1, IL-6, and TNF-a, by infiltrating monocytes
and macrophages, and of RANKL by activated T cells.
Subsequently, these events could induce osteoclast for-
mation around tophi and in osteolytic lesions. Further-
more, TRAP+ osteoclasts (possibly derived from
macrophages) present in the vicinity of tophus could par-
ticipate in the recruitments of T and B cells. Thus, we
propose that pro-resorptive cytokines, such as IL-1, IL-6,
TNF-a and RANKL, contribute to osteoclastic bone
resorption in patients with chronic gout.
Conclusions
This study shows cellular and humoral evidence of bone
destruction in gouty tophus tissues, and demonstrates
that MSU crystals have the capacity to induce pro-
resorptive cytokines. In addition, we report a novel
observation on the implication of RANKL in the patho-
genesis of gouty bone erosion. These findings provide
important information for the exploration of therapeutic
strategies to prevent bone destruction in chronic gout.
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